|
|
Volumn 50, Issue 6, 2011, Pages 1019-1024
|
|
ANCA vasculitis: time for a change in treatment paradigm? Not yet.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
AZATHIOPRINE;
CYCLOPHOSPHAMIDE;
FLUOROURACIL;
GLUCOCORTICOID;
IMMUNOSUPPRESSIVE AGENT;
MITOMYCIN;
MONOCLONAL ANTIBODY;
RITUXIMAB;
SEMUSTINE;
ANCA ASSOCIATED VASCULITIS;
DRUG COMBINATION;
FEMALE;
HOSPITALIZATION;
HUMAN;
IMMUNOLOGY;
MALE;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
REMISSION;
REVIEW;
RISK ASSESSMENT;
TREATMENT OUTCOME;
ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS;
ANTIBODIES, MONOCLONAL, MURINE-DERIVED;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
AZATHIOPRINE;
CYCLOPHOSPHAMIDE;
DRUG THERAPY, COMBINATION;
FEMALE;
FLUOROURACIL;
GLUCOCORTICOIDS;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
MALE;
MITOMYCIN;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
REMISSION INDUCTION;
RISK ASSESSMENT;
SEMUSTINE;
SEVERITY OF ILLNESS INDEX;
TREATMENT OUTCOME;
|
|
EID: 80053909074
PISSN: None
EISSN: 14620332
Source Type: Journal
DOI: 10.1093/rheumatology/ker002 Document Type: Review |
|
Times cited : (11)
|
|
References (0)
|
